| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b91f81d741def5fb07a38abbbfa56ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9aa53bf98f8a8797812789d863728a80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59de8c77a8f703a97b6cef7aad1e499e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-16 |
| filingDate |
2018-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_042288cb7bc5022e5130002ea32f2624
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db44ac26a88d3e20b1635a9cbdde6742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2bfc5e3b98cca0c81a6d173e897be1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0f48ad08f1962a5444326b4e6c8bbd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69d633d22b91e8a995677480a127fe8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcb0dc632eab00bf43cc9d478e88d86c |
| publicationDate |
2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112019027292-A2 |
| titleOfInvention |
coumarin-like cyclic compound as a mek inhibitor and use of it |
| abstract |
a class of cyclic coumarin-like compounds is disclosed as mek inhibitors and pharmaceutical compositions comprising the compounds, and their use in the preparation of a medicament for the treatment of mek-related diseases. particularly compounds as shown in formula (i) and pharmaceutically acceptable salts thereof or tautomers thereof are disclosed. |
| priorityDate |
2017-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |